These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Clin Infect Dis; 2009 Jul 15; 49(2):205-12. PubMed ID: 19508165 [Abstract] [Full Text] [Related]
6. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, Rubinstein U, Dagan R, Israeli Bacteremia and Meningitis Active Surveillance Group. Vaccine; 2012 Oct 12; 30(46):6600-7. PubMed ID: 22939907 [Abstract] [Full Text] [Related]
7. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. Muñoz-Almagro C, Ciruela P, Esteva C, Marco F, Navarro M, Bartolome R, Sauca G, Gallés C, Morta M, Ballester F, Raga X, Selva L, Catalan study group of invasive pneumococcal disease. J Infect; 2011 Aug 12; 63(2):151-62. PubMed ID: 21679725 [Abstract] [Full Text] [Related]
8. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL. Clin Infect Dis; 2008 Aug 15; 47(4):476-84. PubMed ID: 18627249 [Abstract] [Full Text] [Related]
9. Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon. Hanna-Wakim R, Chehab H, Mahfouz I, Nassar F, Baroud M, Shehab M, Pimentel G, Wasfy M, House B, Araj G, Matar G, Dbaibo G, Lebanese Inter-Hospital Pneumococcal Surveillance Program. Vaccine; 2012 Dec 31; 30 Suppl 6():G11-7. PubMed ID: 23228352 [Abstract] [Full Text] [Related]
10. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Isaacman DJ, McIntosh ED, Reinert RR. Int J Infect Dis; 2010 Mar 31; 14(3):e197-209. PubMed ID: 19700359 [Abstract] [Full Text] [Related]
11. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006. Motlova J, Benes C, Kriz P. Epidemiol Infect; 2009 Apr 31; 137(4):562-9. PubMed ID: 18796171 [Abstract] [Full Text] [Related]
12. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Techasaensiri C, Messina AF, Katz K, Ahmad N, Huang R, McCracken GH. Pediatr Infect Dis J; 2010 Apr 31; 29(4):294-300. PubMed ID: 19949357 [Abstract] [Full Text] [Related]
13. Pneumococcal disease in South Australia: vaccine success but no time for complacency. Johnson DR, D'Onise K, Holland RA, Raupach JC, Koehler AP. Vaccine; 2012 Mar 09; 30(12):2206-11. PubMed ID: 22273663 [Abstract] [Full Text] [Related]
14. Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. Pichon B, Ladhani SN, Slack MP, Segonds-Pichon A, Andrews NJ, Waight PA, Miller E, George R. J Clin Microbiol; 2013 Mar 09; 51(3):820-7. PubMed ID: 23269742 [Abstract] [Full Text] [Related]
15. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, Santosham M, O'Brien KL. Clin Infect Dis; 2010 May 01; 50(9):1238-46. PubMed ID: 20367225 [Abstract] [Full Text] [Related]
16. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L, Danish Pneumococcal Surveillance Collaboration Group 2009-2010. Vaccine; 2012 Jun 06; 30(26):3944-50. PubMed ID: 22504662 [Abstract] [Full Text] [Related]
17. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta. Leal J, Vanderkooi OG, Church DL, Macdonald J, Tyrrell GJ, Kellner JD. Pediatr Infect Dis J; 2012 Sep 06; 31(9):e169-75. PubMed ID: 22673137 [Abstract] [Full Text] [Related]
18. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Clin Infect Dis; 2014 Oct 15; 59(8):1066-73. PubMed ID: 25034421 [Abstract] [Full Text] [Related]
19. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. van der Linden M, Weiß S, Falkenhorst G, Siedler A, Imöhl M, von Kries R. Vaccine; 2012 Aug 31; 30(40):5880-5. PubMed ID: 22771186 [Abstract] [Full Text] [Related]